Cyclo Therapeutics, Inc. CYTH
We take great care to ensure that the data presented and summarized in this overview for Cyclo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTH
View all-
Epiq Capital Group, LLC San Francisco, CA739KShares$465,8380.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$377,1770.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$302,8467.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$95,9690.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$69,31418.16% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$37,4910.0% of portfolio
-
State Street Corp Boston, MA39.5KShares$24,9030.0% of portfolio
-
Wealth Enhancement Advisory Services, LLC23.4KShares$14,7420.0% of portfolio
-
Northern Trust Corp Chicago, IL21.7KShares$13,6840.0% of portfolio
-
Ubs Group Ag12.5KShares$7,8480.0% of portfolio
Latest Institutional Activity in CYTH
Top Purchases
Top Sells
About CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Insider Transactions at CYTH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Ce Rick Strattan Director |
BUY
Grant, award, or other acquisition
|
Direct |
63,608
+14.7%
|
-
|
|
Nov 15
2024
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,022
+8.4%
|
-
|
|
Nov 15
2024
|
William S Shanahan Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,145
+9.24%
|
-
|
|
Nov 15
2024
|
Shawn Cross Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,228
+13.78%
|
-
|
|
Nov 15
2024
|
William Conkling Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,660
+24.91%
|
-
|
|
Nov 15
2024
|
Vivien Wong Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,145
+27.61%
|
-
|
|
Nov 15
2024
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,067
+12.1%
|
-
|
|
Aug 16
2024
|
Shawn Cross Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,028
+9.07%
|
-
|
|
Aug 16
2024
|
Vivien Wong Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,937
+24.42%
|
-
|
|
Aug 16
2024
|
William Conkling Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,731
+20.64%
|
-
|
|
Aug 16
2024
|
William S Shanahan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,937
+5.6%
|
-
|
|
Aug 16
2024
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,354
+5.02%
|
-
|
|
Aug 16
2024
|
Ce Rick Strattan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,524
+3.02%
|
-
|
|
Aug 16
2024
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,516
+7.72%
|
-
|
|
Jun 03
2024
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,352
+8.24%
|
-
|
|
Jun 03
2024
|
Ce Rick Strattan Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+3.07%
|
-
|
|
Jun 03
2024
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,743
+2.99%
|
-
|
|
Jun 03
2024
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,067
+5.21%
|
-
|
|
Jun 03
2024
|
William S Shanahan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,813
+5.85%
|
-
|
|
Jun 03
2024
|
William Conkling Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,594
+25.71%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 467K shares |
|---|